| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | COLL Collegium Pharmaceutical, Inc. | Dieter David | EVP &General Counsel | Sell | 13,976 | $34.92 | $488,099.22 | -15.4% | - | - | |
| Mar 16, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $537.81 | $5,109,148.28 | -16.5% | - | - | |
| Mar 13, 2026 | ANIP Ani Pharmaceuticals, Inc. | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 500 | $72.62 | $36,310.00 | -0.6% | - | - | |
| Mar 13, 2026 | ANIP Ani Pharmaceuticals, Inc. | Mutz Christopher | Head Of Rare Disease | Sell | 3,162 | $71.64 | $226,525.68 | -3.3% | - | - | |
| Mar 11, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $539.54 | $5,125,646.80 | -14.7% | +0.9% | - | |
| Mar 11, 2026 | ANIP Ani Pharmaceuticals, Inc. | Rowland Thomas Andrew | SVP, Head - Established Brands | Sell | 4,772 | $74.91 | $357,470.52 | -11.0% | +6.3% | - | |
| Mar 10, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $539.71 | $5,127,273.03 | -10.7% | +2.6% | - | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, Inc. | Braender Lori J | Chief Legal Officer | Sell | 40,102 | $4.17 | $167,345.65 | -8.3% | -6.4% | - | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, Inc. | Boyd Peter E.81 | Chief People Officer | Sell | 29,814 | $4.17 | $124,413.82 | -8.1% | -6.4% | - | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, Inc. | Jung Cassie | Chief Operating Officer | Sell | 45,791 | $4.17 | $191,085.84 | -14.3% | -6.4% | - | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, Inc. | Cioffi Melina | SVP, Regulatory Affairs | Sell | 25,311 | $4.17 | $105,622.80 | -8.4% | -6.4% | - | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, Inc. | Korczynski Sherry | Chief Commercial Officer | Sell | 15,741 | $4.17 | $65,687.19 | -6.1% | -6.4% | - | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, Inc. | Toth A Ernest Jr | Chief Financial Officer | Sell | 58,254 | $4.17 | $243,093.94 | -13.4% | -6.4% | - | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, Inc. | Barber Daniel72 | President And CEO | Sell | 180,677 | $4.17 | $753,965.12 | -15.2% | -6.4% | - | |
| Mar 9, 2026 | KNSA Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | Chief Financial Officer | Sell | 36,722 | $45.92 | $1,686,157.82 | -46.1% | - | - | |
| Mar 9, 2026 | COLL Collegium Pharmaceutical, Inc. | Dieter David | EVP &General Counsel | Sell | 6,224 | $36.65 | $228,109.60 | -6.4% | -10.4% | - | |
| Mar 9, 2026 | ORGO Organogenesis Holdings Inc. | Leibowitz Arthur S | Director | Buy | 5,000 | $2.68 | $13,405.00 | +1.7% | -18.8% | - | |
| Mar 9, 2026 | LQDA Liquidia Corporation | Moomaw Scott | Chief Commercial Officer | Sell | 80,000 | $35.32 | $2,825,824.00 | -29.7% | - | - | |
| Mar 9, 2026 | ORGO Organogenesis Holdings Inc. | Driscoll Michael Joseph | Director | Buy | 10,000 | $2.67 | $26,688.00 | +4.6% | -18.8% | - | |
| Mar 9, 2026 | INDV Indivior Pharmaceuticals, Inc. | Ryan Barbara | Director | Buy | 31 | $32.56 | $1,009.36 | +0.5% | - | - | |
| Mar 6, 2026 | INDV Indivior Pharmaceuticals, Inc. | Kingsley Stuart A | Director | Buy | 940 | $31.87 | $29,953.10 | +20.2% | +8.1% | - | |
| Mar 6, 2026 | PLNH Planet 13 Holdings Inc. | Wren Chris | VP Of Operations | Sell | 30,000 | $0.16 | $4,854.00 | -0.7% | - | - | |
| Mar 5, 2026 | UTHR United Therapeutics Corporation | Mahon Paul A47 | EVP &General Counsel | Sell | 8,300 | $483.16 | $4,010,187.14 | -2.2% | +12.9% | - | |
| Mar 4, 2026 | UTHR United Therapeutics Corporation | Kurzweil Ray | Director | Sell | 4,910 | $489.02 | $2,401,088.20 | -27.9% | +11.1% | - | |
| Mar 4, 2026 | UTHR United Therapeutics Corporation | Causey Christopher59 | Director | Sell | 20 | $490.17 | $9,803.37 | -0.5% | +11.1% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.